• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

    6/23/25 8:00:00 AM ET
    $JUNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JUNS alert in real time by email

    Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation

    Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Annika Sörenstam, the most accomplished female professional golfer in history, has joined the Company as the first official brand ambassador for Nugevia™, Jupiter Neurosciences' new consumer longevity supplement line.

    Annika, who has amassed over 95 international tournament victories—including 72 LPGA titles and 10 major championships—will collaborate with the Company to champion Nugevia's science-backed formulations designed for performance, focus, and cellular vitality.

    "Annika embodies everything Nugevia™ stands for—longevity, clarity, and peak performance supported by real science," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "As someone who has remained competitive well beyond her touring years, Annika is a powerful advocate for our mission to support healthy aging and optimal function at any stage of life."

    Hall of Fame golfer, Annika stated, "My first thought when I was asked to collaborate on the development and marketing of was "show me the science!" I have a strong interest in living a healthy, active lifestyle, and as a professional athlete, when I use a product, I want to know that there is strong science behind it. I found this to be the case with Nugevia."

    Nugevia™ is built on JOTROL™, Jupiter's patented resveratrol-based micellar delivery platform that has demonstrated significantly enhanced bioavailability and underpins the Company's clinical-stage CNS therapies. The three debut formulations—GLO, MND, and PWR—are designed to support cellular resilience through intelligent stacking of synergistic ingredients, all enhanced for optimal absorption via the JOTROL™ system.

    Annika added, "After spending over 40 years under the sun as a professional golfer, I've learned how critical it is to protect and nourish my skin. Nugevia GLO helps support that by promoting cellular defense and skin vitality from the inside out. In golf, business, and especially motherhood, mental clarity and focus are everything—but staying sharp doesn't get easier with age. Nugevia MND supports cognitive resilience so I can stay mentally on top of my game, no matter what the day brings. And when I'm competing or staying active, muscle recovery and energy matter more than ever. Nugevia PWR helps replenish mitochondrial function, which is key for sustained strength and performance—especially when I'm up against the younger generation. At the end of the day, we all want to look younger, stay sharper, and feel stronger. Nugevia offers science-backed solutions that help you do just that—in golf and in life."

    The Nugevia™ brand reflects Jupiter's dual-path strategy—advancing clinically validated therapeutics while tapping into the rapidly growing longevity market, projected to reach $8 trillion by 2030. This consumer-facing arm is expected to create a revenue stream that supports ongoing clinical development, corporate operating costs and enhances long-term shareholder value.

    A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/.

    About Jupiter Neurosciences, Inc.

    Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, includeing indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website www.jupiterneurosciences.com.

    About JOTROL

    Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.

    Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson's Disease.

    In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter's Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.

    About Annika

    During her 15-year, Hall-of-Fame career, Annika rewrote the LPGA and Ladies European Tour record books, won countless awards, and changed the way women's golf was played, viewed and covered. She amassed over 95 worldwide wins, 72 on the LPGA Tour, 10 Major Championships, and the 2021 US Senior Women's Open. She won a record eight Rolex Player of the Year awards, in 2003 was the first woman in 58 years to play a PGA TOUR event, is the only LPGA player to shoot 59, and is still the LPGA's All-Time money leader with over $22 Million in earnings despite stepping away from competition in 2008.

    In 2007, she created the ANNIKA Foundation, which currently hosts seven global tournaments with over 800 junior girls from 60 different countries competing annually. In 2014 it started the ANNIKA Intercollegiate presented by 3M, featuring 12 of the top DI schools in the country. The winner gets an invite into The ANNIKA Driven by Gainbridge at Pelican, the only signature event on the LPGA schedule.

    In 2014 the Rolex ANNIKA Major Award was established to recognize the player who, during a current LPGA Tour season, has the most outstanding record in all five major championships. In 2020, Annika was elected the President of the International Golf Federation which oversees golf in the Olympic Games. In 2021, she became the first female golfer to receive the Presidential Medal of Freedom.

    In 2022, the ANNIKA Development Program was established in partnership with Old Barnwell, a private golf club near Aiken, South Carolina to support college graduates who are pursuing professional golf careers. Four ANNIKA Ambassadors are selected per year, and they receive access for three years to Old Barnwell, housing, financial assistance, training, and mentorship from Annika.

    The ANNIKA Women's All Pro Tour was launched in 2024 to provide a better pathway for women to the Epson and LPGA Tours. In 2025, the Foundation launched the More Than Golf Invitational for women's Mid-Major Conference Champions. The college player of the year wins the ANNIKA Award Presented by Stifel.

    FORWARD-LOOKING STATEMENTS

    Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

    Contact:

    Dave Gentry

    RedChip Companies, Inc.

    1-407-644-4256

    1-800-RED-CHIP (733-2447)

    [email protected]



    Primary Logo

    Get the next $JUNS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JUNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JUNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Jupiter Neurosciences Inc.

      10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      5/15/25 4:31:24 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Jupiter Neurosciences Inc.

      8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      4/21/25 12:38:15 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Jupiter Neurosciences Inc.

      10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)

      3/28/25 5:01:29 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

      PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, proje

      6/30/25 3:15:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science

      GLO targets the growing "beauty-from-within" market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, is pleased to unveil Nugevia™ GLO—a pioneering "beauty-from-within" supplement designed to elevate the standard of skin health through clinically validated cellular science. GLO is a daily supplement designed to support radiant, resilient skin from the inside out by promoting cellular defense, collagen integrity, and hydration. Unmatched Scienc

      6/27/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

      Partnership supports near-term launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, June 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that Annika Sörenstam, the most accomplished female professional golfer in history, has joined the Company as the first official brand ambassador for Nugevia™, Jupiter Neurosciences' new consumer longevity supplement line. Annika, who has amassed over 95 international tournament victories—including 72 LPGA titles and 10 major championships—will collaborate with the Company to champion Nugevia's science-backed formulations designed for performance, f

      6/23/25 8:00:00 AM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JUNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres + Chief Business Officer Silva Alison D. bought $772 worth of shares (750 units at $1.03), increasing direct ownership by 0.67% to 112,777 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 8:56:52 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Rosen Christer bought $3,667 worth of shares (3,600 units at $1.02), increasing direct ownership by 0.03% to 11,078,892 units (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/3/25 2:53:00 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pres + Chief Business Officer Silva Alison D. converted options into 110,227 shares and bought $1,855 worth of shares (1,800 units at $1.03) (SEC Form 4)

      4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)

      7/1/25 7:55:51 PM ET
      $JUNS
      Biotechnology: Pharmaceutical Preparations
      Health Care